Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALG-1001 in Diabetic Macular Edema
NCT01482871Phase 2Withdrawn
- Sponsor
- Allegro Ophthalmics, LLC
- Start
- Jan 2011
- Primary completion
- Nov 2011
- Countries
- 1
01
Overview
A Phase 2 trial of risuteganib in diabetic macular edema (DME), sponsored by Allegro Ophthalmics, LLC. Planned start Jan 2011; status: withdrawn.
02
Drugs
risuteganib
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT01482871.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01482871.